To investigate the effect of intraperitoneal injection of α-GalCer on non-alcoholic fatty liver- DOI:10.3969/j.issn.1000-1565.2021.06.007腹腔注射α-GalCer对非酒精性脂肪性肝病的影响梁蕊1,2,高翔1,2,滕景芳1,2,王建国3,程树杰3,4,孟明1,2(1.河北大学 基础医学院,河北 保定 071000; 2.河北省炎性自身免疫性疾病发病机制及防治重点实验室,河北 保定 071000; 3.河北大学附属医院 肝胆外科,河北 保定 071000; 4.河北省普通外科数字医学基础研究重点实验室,河北 保定 071000)摘 要:探讨了腹腔注射α-GalCer对非酒精性脂肪性肝病(NAFLD)的影响,为以iNKT细胞为靶点的NAFLD免疫学防治奠定基础.利用高脂饲料或蛋氨酸/胆碱缺乏饲料分别喂养C57BL/6J小鼠,建立非酒精性脂肪肝(NAFL)模型和非酒精性脂肪性肝炎(NASH)模型.全自动生化分析仪分析小鼠外周血中TCH、TG、HDL、LDL、ALT及AST水平;H&E染色观察肝脏病理变化;流式细胞术检测肝脏iNKT、iNKT1、iNKT2细胞频率.与对照组相比,NAFL小鼠体质量升高,血清TCH、HDL、LDL及ALT水平升高,肝脏脂肪沉积增加;而NASH小鼠体质量降低,血清TCH、TG及LDL水平降低,肝脏脂肪沉积增加并伴有炎细胞浸润.腹腔注射α-GalCer后,NAFL小鼠血清TCH、HDL及LDL水平降低,肝脏脂肪沉积减少,肝脏iNKT2亚群比例增加;NASH小鼠血清ALT和AST水平升高,肝脏脂肪沉积减少,炎细胞浸润增加,肝脏iNKT1、iNKT2亚群比例增加,其中以iNKT1亚群增加为主.腹腔注射α-GalCer可以改善NAFL和NASH小鼠肝脏脂肪沉积;小鼠NAFLD发病不同阶段(NAFL或NASH)肝脏局部微环境的改变可能影响α-GalCer对肝脏iNKT细胞不同亚群的激活,为进一步研究NAFLD的发病机制及免疫学治疗策略提供了有价值的实验数据.关键词:非酒精性脂肪性肝病;非酒精性脂肪肝;非酒精性脂肪性肝炎;iNKT;α-GalCer中图分类号:R392.5 文献标志码:A 文章编号:1000-1565(2021)06-0672-10Effect of intraperitoneal injection of α-GalCer on nonalcoholic fatty liver diseaseLIANG Rui1,2, GAO Xiang1,2, TENG Jingfang1,2, WANG Jianguo3, CHENG Shujie3,4, MENG Ming1,2(1. College of Basic Medicine, Hebei University, Baoding 071000, China;2. Key Laboratory of Pathogenesis Mechanism and Control of Inflammatory-autoimmune Diseases in Hebei Province, Baoding 071000, China;3. Department of Hepatobiliary Surgery, Affiliated Hospital of Hebei University, Baoding 071000, China;4. Key Laboratory of General Surgery Digital Medicine Basic Researchin Hebei Province, Baoding 071000, China)Abstract: To investigate the effect of intraperitoneal injection of α-GalCer on non-alcoholic fatty liver- 收稿日期:2021-05-23 基金项目:国家自然科学基金面上项目(81771755);河北省自然科学基金资助项目(H2020201022;H2020201300) 第一作者:梁蕊(1995—),女,河北沧州人,河北大学在读硕士研究生,主要从事非酒精性脂肪性肝病研究.E-mail: liangrui1208@163.com 通信作者:孟明(1964—),女,辽宁义县人,河北大学教授,博士,博士生导师,主要从事自身免疫性疾病及免疫药理学研究.E-mail: mengming127@163.com程树杰(1965—),男,河北安国人,河北大学教授,博士生导师,主要从事肝胆胰脾疾病等研究.E-mail: shujiecheng@yeah.net第6期梁蕊等:腹腔注射α-GalCer对非酒精性脂肪性肝病的影响disease, and to lay a foundation for immunological prevention and treatment of non-alcoholic fatty liver disease(NAFLD)targeting iNKT cells. Nonalcoholic fatty liver disease(NAFL)model and nonalcoholic steatohepatitis(NASH)model were established by feeding C57BL/6J mice with high fat diet or methionine/choline deficiency diet. The levels of TCH, TG, HDL, LDL, ALT and AST in the peripheral blood of mice were analyzed by automatic biochemical analyzer. The pathological changes of liver were observed by H&E staining. The cell frequencies of iNKT, iNKT1 and iNKT2 in liver were detected by flow cytometry. Compared with the control group, the body weight of NAFL mice increased, the serum levels of TCH, HDL, LDL, ALT increased, and the hepatic fat deposition increased. While the body weight of NASH mice decreased, the serum levels of TCH、TG and LDL decreased, liver fat deposition is increased with inflammatory cell infiltration. After intraperitoneal injection of α-GalCer, serum levels of TCH, HDL, LDL decreased, liver fat deposition decreased,and the proportion of liver iNKT2 subsets increased in NAFL mice. While the serum levels of ALT and AST increased, liver fat deposition decreased, inflammatory cell infiltration increased and the proportion of liver iNKT1 and iNKT2 subsets increased, but mainly iNKT1 subsets in NASH mice. Intraperitoneal injection α-GalCer can improve NAFL and NASH mice liver fat deposition; changes in local microenvironment in different stages of NAFLD in mice(NAFL or NASH)may affect the activation of α-GalCer to different subgroups of liver iNKT cells, which provides valuable experimental data for further study of the pathogenesis and immunological treatment strategies of NAFLD.
[1] 中华医学会肝病学分会脂肪肝和酒精性肝病学组. 酒精性肝病诊疗指南(2010年修订版)[J]. 中华肝脏病杂志, 2010, 18(3): 167-170. DOI:10.3760/cma.j.issn.1007-3418.2010.03.003.
[2] CARR R M, ORANU A, KHUNGAR V. Nonalcoholic fatty liver disease: pathophysiology and management[J]. Gastroenterol Clin North Am, 2016, 45(4):639-652. DOI:10.1016/j.gtc.2016.07.003.
[3] SWEET P H, KHOO T, NGUYEN S. Nonalcoholic Fatty Liver Disease[J]. Primary Care: Clinics in Office Practice, 2017, 44(4):599-607. DOI:10.1016/j.pop.2017.07.003.
[4] SOMAYA A, ARUN S. Recent advances in understanding and managing non-alcoholic fatty liver disease[J]. F1000research, 2018, 7:720. DOI:10.12688/f1000research.14421.1.
[5] PAREDES A H, TORRES D M, HARRISON S A. Nonalcoholic fatty liver disease.[J]. Clinics in Liver Disease, 2012, 16(2):397-419. DOI:10.1016/j.cld.2012.03.005.
[6] NORBERT STEFAN M D, HANS-ULRICH HÄRINGMD, KENNETH CUSI MD, et al. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies.[J]. The Lancet Diabetes Endocrinology, 2019, 7(4): 313-324. DOI:10.1016/S2213-8587(18)30154-2.
[7] YASUHIKO M, RIEKO K, TOSHIHIRO I, et al. Predominant expression of invariant Vα14+ TCR α chain in NK1.1+ T cell populations[J]. International Immunology,1995,7(7):1157-1161. DOI:10.1093/intimm/7.7.1157.
[8] BROSSAY L, CHIODA M, BURDIN N, et al. CD1d-mediated recognition of an α-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution[J]. The Journal of Experimental Medicine, 1998, 188(8): 1521-1528.. DOI: 10.1084/jem.188.8.1521.
[9] SAKUISHI K, OKI S, ARAKI M, et al. Invariant NKT Cells Biased for IL-5 Production Act as Crucial Regulators of Inflammation[J]. Journal of Immunology, 2007, 179(6):3452-3462. DOI: 10.4049/jimmunol.179.6.3452.
[10] CERUNDOLO V, SILK J D, MASRI S H, et al. Harnessing invariant NKT cells in vaccination strategies[J]. Nature Reviews Immunology,2009,9:28-38DOI: 10.1038/nri2451.
[11] HEGDE S, CHEN X, KEATON J M, et al. NKT cells direct monocytes into a DC differentiation pathway[J]. Journal of Leukocyte Biology, 2007, 81(5): 1224-1235. DOI:10.1189/jlb.1206718.
[12] KWON D I, LEE Y J. Lineage differentiation program of invariant natural killer T cells[J]. Immune Network, 2017, 17(6): 365. DOI:10.4110/in.2017.17.6.365.
[13] HORIKOSHI M, GOTO D, SEGAWA S, et al. Activation of invariant NKT cells with glycolipid ligand α-galactosylceramide ameliorates glucose-6-phosphate isomerase peptide-induced arthritis[J]. PLoS ONE, 2012, 7(12):e51215. DOI:10.1371/journal.pone.0051215.
[14] BARTHELEMY A, IVANOV S, HASSANE M, et al. Exogenous activation of invariant natural killer T cells by α-galactosylceramide reduces pneumococcal outgrowth and dissemination postinfluenza[J]. mBio, 2016, 7(6):e01440-16. DOI:10.1128/mBio.01440-16.
[15] ZHANG Y, SPRINGFIELD R, CHEN S, et al. α-GalCer and iNKT Cell-Based Cancer Immunotherapy: Realizing the Therapeutic Potentials[J]. Frontiers in Immunology, 2019, 10:1126-. DOI:10.3389/fimmu.2019.01126.
[16] VAHEDI G, KANNO Y, FURUMOTO Y, et al. Super-enhancers delineate disease-associated regulatory nodes in T cells[J]. Nature, 2015, 520(7548):558-562. DOI:10.1038/nature14154.
[17] MATSUDA J L, MALLEVAEY T, SCOTT-BROWNE J, et al. CD1d-restricted iNKT cells, the Swiss-Army knife of the immune system.[J]. Current Opinion in Immunology, 2008, 20(3):358-368. DOI:10.1016/j.coi.2008.03.018.
[18] ZHU S, ZHANG H, BAI L. NKT cells in liver diseases[J]. Frontiers of Medicine, 2018, 12(3):249-261. DOI:10.1007/s11684-018-0622-3.
[19] KUMAR, VIPIN. NKT-cell subsets: Promoters and protectors in inflammatory liver disease[J]. Journal of Hepatology, 2013, 59(3):618-620. DOI:10.1016/j.jhep.2013.02.032.
[20] MENG M, CHEN S, GAO X, et al. Activation of invariant natural killer T cell subsets in C57BL/6J mice by different injection modes of α-galactosylceramide[J]. Iran J Allergy Asthma Immunol, 2020, 19(1): 35-44. DOI:10.18502/ijaai.v19i1.2416.
[21] CHEN D Z, GAO X, WANG J G, et al. Activation of hepatic iNKT2 cells by α-GalCer ameliorates hepatic steatosis induced by high-fat diet in C57BL/6J mice[J]. Int Immunopharmacol, 2019, 74: 105727. DOI:10.1016/j.intimp.2019.105727.
[22] TAKAHASHI Y, SOEJIMA Y, FUKUSATO T. Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis[J]. World J Gastroenterol, 2012, 18(19):2300-2308. DOI:10.3748/wjg.v18.i19.2300.
[23] PATEL D P, YAN T, KIM D, et al. Withaferin A improves nonalcoholic steatohepatitis in mice[J]. Journal of Pharmacology and Experimental Therapeutics, 2019, 371(2): 360-374. DOI:10.1124/jpet.119.256792.
[24] HEBBAED L, GEORGE J. Animal models of nonalcoholic fatty liver disease[J]. Nat Rev Gastroenterol Hepatol, 2011, 8(1):35-44. DOI:10.1038/nrgastro.2010.191.
[25] SUNG-BAE KIM, OK-HWA, YOUNG-SEOB Lee, et al. Hepatoprotective Effect and Synergism of Bisdemethoycurcumin against MCD Diet-Induced Nonalcoholic Fatty Liver Disease in Mice.[J]. PLOS ONE, 2016, 11(2):e0147745. DOI:10.1371/journal.pone.0147745
[26] AYAE IKAWA-YOSHIDA, SAORI MATSUO, ATSUHIKO KATO,et al. Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet[J]. International Journal of Experimental Pathology, 2017,98(4): 221-233.. DOI:10.1111/iep.12240
[27] TAJIRI K, SHIMIZU Y. Role of NKT cells in the pathogenesis of NAFLD[J]. Int J Hepatol, 2012, 2012: 850836. DOI:10.1155/2012/850836.
[28] SZCZEPANKIEWICZ D, SKRZYPSKI M, PRUSZYN 'SKA-OSZMAŁEK E, et al. Interleukin 4 affects lipid metabolism and the expression of pro-inflammatory factors in mature rat adipocytes[J]. Immunobiology, 2018, 223(11): 677-683. DOI:10.1016/j.imbio.2018.07.014.
[29] WEISS S T. Obesity: insight into the origins of asthma[J]. Nat Immunol, 2005, 6(6): 537-539. DOI:10.1038/ni0605-537. (
